Baidu
map

Biological Psychiatry:抗抑郁症研究成果

2018-12-15 佚名 北京大学医学部

2018年12月6日,北京大学药学院天然药物及仿生药物国家重点实验室黄卓研究员课题组和基础医学院梁静副教授课题组合作,在国际著名精神病学杂志《生物精神病学》(Biological Psychiatry, IF=11.982)上在线发表了题为“CDYL-mediated histone crotonylation regulates stress-induced depressive behavio

2018年12月6日,北京大学药学院天然药物及仿生药物国家重点实验室黄卓研究员课题组和基础医学院梁静副教授课题组合作,在国际著名精神病学杂志《生物精神病学》(Biological Psychiatry, IF=11.982)上在线发表了题为“CDYL-mediated histone crotonylation regulates stress-induced depressive behaviors”的研究论文。该研究阐明了社交挫败抑郁模型中,前脑组蛋白巴豆酰化修饰(histone crotonylation)与表观遗传分子CDYL在抑郁症发生和发展中的作用及其分子机制,为抑郁症的治疗提供了潜在的干预靶点。

抑郁症(depression)是一种现代社会中最为普遍的精神疾病,影响全球超过三亿人的正常生活。抑郁症的发生不仅受基因遗传学的调控,也与环境应激如压力、创伤记忆等因素密切相关,但环境应激导致抑郁发病的分子机制仍不清楚。该研究团队围绕环境应激导致大脑的表观遗传学改变进行研究,以表观遗传因子CDYL调控的组蛋白巴豆酰化修饰为切入点,对应激导致的抑郁发病机制进行研究。


VGF敲低可以明显降低PL脑区的树突棘数目

黄卓研究团队以慢性社交挫败应激(chronic social defeat stress)为模型,发现一个组蛋白巴豆酰化水解酶和转录抑制因子CDYL,在抑郁小鼠前边缘皮层(PL, prelimbic cortex)的表达量显着上升,并且它所介导的组蛋白巴豆酰化水平显着下降。在PL过表达CDYL时,可以增加小鼠对抑郁的易感性;反之,敲低CDYL可以降低小鼠对抑郁的易感性。通过RNA-seq高通量测序,研究团队发现CDYL可以通过转录抑制神经肽VGF的表达来影响神经突触的可塑性,从而调节压力介导的抑郁症发生发展。这一工作首次报道了组蛋白巴豆酰化修饰在抑郁症中的作用,并从分子机制上将外界环境应激与抑郁症的发病相联系。因此,这项工作不仅为阐释抑郁症发生发展提供了新的理论,还为抑郁症的治疗提供了新的靶点和潜在药物,具有重要的理论和应用意义。


CDYL通过调节VGF的表达来影响小鼠的抑郁状行为

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918431, encodeId=9e51191843125, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 25 23:21:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767579, encodeId=18691e6757933, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jun 19 11:21:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898485, encodeId=b080189848536, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Jan 01 07:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792134, encodeId=10af1e92134d0, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Apr 03 23:21:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492235, encodeId=f4a91492235a9, content=<a href='/topic/show?id=7999553333c' target=_blank style='color:#2F92EE;'>#抗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55333, encryptionId=7999553333c, topicName=抗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a59b8920619, createdName=wushaoling, createdTime=Mon Dec 17 12:21:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
    2019-08-25 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918431, encodeId=9e51191843125, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 25 23:21:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767579, encodeId=18691e6757933, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jun 19 11:21:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898485, encodeId=b080189848536, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Jan 01 07:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792134, encodeId=10af1e92134d0, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Apr 03 23:21:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492235, encodeId=f4a91492235a9, content=<a href='/topic/show?id=7999553333c' target=_blank style='color:#2F92EE;'>#抗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55333, encryptionId=7999553333c, topicName=抗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a59b8920619, createdName=wushaoling, createdTime=Mon Dec 17 12:21:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918431, encodeId=9e51191843125, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 25 23:21:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767579, encodeId=18691e6757933, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jun 19 11:21:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898485, encodeId=b080189848536, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Jan 01 07:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792134, encodeId=10af1e92134d0, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Apr 03 23:21:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492235, encodeId=f4a91492235a9, content=<a href='/topic/show?id=7999553333c' target=_blank style='color:#2F92EE;'>#抗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55333, encryptionId=7999553333c, topicName=抗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a59b8920619, createdName=wushaoling, createdTime=Mon Dec 17 12:21:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918431, encodeId=9e51191843125, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 25 23:21:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767579, encodeId=18691e6757933, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jun 19 11:21:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898485, encodeId=b080189848536, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Jan 01 07:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792134, encodeId=10af1e92134d0, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Apr 03 23:21:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492235, encodeId=f4a91492235a9, content=<a href='/topic/show?id=7999553333c' target=_blank style='color:#2F92EE;'>#抗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55333, encryptionId=7999553333c, topicName=抗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a59b8920619, createdName=wushaoling, createdTime=Mon Dec 17 12:21:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918431, encodeId=9e51191843125, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 25 23:21:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767579, encodeId=18691e6757933, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jun 19 11:21:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898485, encodeId=b080189848536, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Jan 01 07:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792134, encodeId=10af1e92134d0, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Apr 03 23:21:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492235, encodeId=f4a91492235a9, content=<a href='/topic/show?id=7999553333c' target=_blank style='color:#2F92EE;'>#抗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55333, encryptionId=7999553333c, topicName=抗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a59b8920619, createdName=wushaoling, createdTime=Mon Dec 17 12:21:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]

相关资讯

Mol Psychiatry:抑郁症临床诊断或有生物标记物

东南大学医学院姚红红教授课题组、东南大学附属中大医院张志珺教授和谢春明研究员课题组以“CircDYM ameliorates depressive-like behavior by targeting miR-9 to regulate microglial activation via HSP90 ubiquitination”为题在Nature出版集团旗下的精神病学杂志《Molecular P

抑郁症机制-脑肠轴作用机制受到广泛关注

长期以来,人类及其肠道内的菌群相互依存,有着共同的进化史。巧合的是,人肠道内微生物的重量竟然和大脑的重量不相上下。而随着时间的推移,人们越来越认识到,脑肠轴在维持大脑健康和压力反应方面起着至关重要的作用,而肠道菌群已经成为这一轴的主要调节器。因此,利用肠道菌群治疗与压力相关精神障碍(如抑郁症)成为可能。在2018年ECNP大会上,来自爱尔兰科克大学的Cryan JF教授提出了这一观点,其指出:近期

Brain:重度抑郁症遗传风险预测遗忘型轻度认知障碍患者向阿尔兹海默症转换的神经生物学机制

天津医科大学总医院、天津市功能影像重点实验室于春水教授课题组最近报道了重度抑郁症遗传风险预测遗忘型轻度认知障碍患者向阿尔兹海默症转换的神经生物学机制,相关研究成果发表在《Brain》,题目为“Neurobiological substrates underlying the effect of genomic risk for depression on the conversion of amn

Nature:抑郁症的大脑发生机制

在一项新的临床前研究中,由生理学教授Scott Thompson博士领导的马里兰大学医学院(UMSOM)的科学家们发现了与“快乐和奖励”相关的大脑活动的变化。

PLOS ONE:免疫相关抑郁症中的抑郁症生物标志物

最近,研究人员进行了一项探究,目的是确定以前未被认识的生物途径和生物标志物,可能会扩大抑郁症的炎症假说。

阿戈美拉汀治疗抑郁症临床应用专家建议

抑郁症具有高患病率、高复发率和疾病负担重等特点, 经规范治疗, 仍有部分患者疗效欠佳或存在残留症状。阿戈美拉汀作为一种新的抗抑郁药, 其作用机制突破了传统单胺递质系统, 特异性激动褪黑素受体, 同时拮抗5- HT2C受体。由于其独特的作用机制, 阿戈美拉汀除了改善抑郁情绪, 还具有调节睡眠和生物节律、性功能影响少、耐受性好、不影响体重、撤药反应小等优势。因为阿戈美拉汀潜在肝功能损害的风险, 临床使

Baidu
map
Baidu
map
Baidu
map